Many hospitals plan to use Russian cancer drug Pembroria

According to the representative of K Hospital, the unit is developing a plan to purchase Pembroria medicine, with an estimated cost of about 36 million VND for each patient's treatment cycle. Updating new drugs in cancer treatment is always of special interest to the unit, but it is necessary to comply with professional procedures and official instructions of the Ministry of Health , as well as the Drug Administration.

“ K Hospital always prioritizes advances in cancer treatment to bring better life chances to patients. However, the introduction of new drugs must be based on scientific basis, treatment recommendations and permission from the management agency, ” said Associate Professor, Dr. Pham Van Binh, Deputy Director of K Hospital.

At K Hospital, treatment will be specific to each patient. Based on many factors, the doctor will advise and provide a suitable treatment regimen to ensure effective treatment for the patient.

Medical experts also said that immunotherapy drugs are used alone or in combination with chemotherapy to increase the response rate and prolong the life of cancer patients. The treatment is aimed at prolonging the patient's life, not as a drug that can completely cure cancer in the late stages.

Some other cancer hospitals in Hanoi and Ho Chi Minh City will also organize open bidding to buy Pembroria according to regulations. If the drug is licensed and wins the bid, the hospitals will use it for patients according to professional instructions.

Pembroria is a biologic drug with the same active ingredient pembrolizumab.

Pembroria is a biological drug with the same active ingredient pembrolizumab as Keytruda, 100mg/4ml vial manufactured by Limited Liability Company "PK-137", Russia, licensed by the Ministry of Health for circulation in Vietnam since October 31.

Pembroria is approved for the following indications: melanoma, non-small cell lung carcinoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma.

Russian cancer drug is indicated for the treatment of esophageal carcinoma, cancer with high-grade microsatellite instability (MSI-H) or mismatch repair defects, cervical cancer, renal cell carcinoma, endometrial carcinoma, breast cancer triple negative, adenocarcinoma of the stomach or gastroesophageal junction, cholangiocarcinoma. The drug is administered by intravenous infusion at a medical facility.

The estimated price of Pembroria is about 18 million VND/bottle, with the usual dose being 2 bottles for 1 treatment cycle. Thus, the cost for a patient's treatment cycle is about 36 million VND with a dose of 200mg (2 bottles).

Medical experts also recommend that not all patients with the cancers listed above are prescribed drugs containing the active ingredient pembrolizumab.

The treatment regimen is based on individualization for each type of disease and each specific stage of each patient. The effectiveness of pembrolizumab-containing drugs depends on many factors such as the patient's condition, tumor mutation type, and disease stage.

In fact, in Vietnam, cancers detected at an early stage have a cure rate of up to 95%, such as breast cancer, nasopharyngeal cancer, and colorectal cancer.

In the early stages, there are cancer Surgery alone can be a radical treatment, the patient does not need to undergo other treatments. Therefore, to detect the disease early, assess the risk of disease, people need to pay attention to regular health check-ups, early detection screening, timely treatment of all types of cancer, thereby increasing the cure rate.

Source: https://baolangson.vn/nhieu-benh-vien-len-ke-hoach-su-dung-thuoc-tri-ung-thu-pembroria-cua-nga-5065426.html